VolitionRx Ltd (VNRX): צמיחת הכנסות מרבעון לרבעון

VolitionRx Limited generates revenue from the sale of diagnostic systems for medicine and veterinary science that analyze nucleosomes. The quarterly revenue growth vector demonstrates sales dynamics, where 157.60 represents the current metric level. Development relies on the commercialization of Nu.Q epigenetic panels and a digital IT platform that optimizes the distribution of oncology tests, increasing the transparency of medical sales channels.
VolitionRx Ltd - פילוחים אנליטיים ומדדי מפתח (VNRX)

Investors use this indicator for the early detection of business stagnation, where decelerating revenue growth rates foreshadow a price correction. The metric measures the percentage deviation of the current quarter's revenue from the previous one, and the change in quarterly sales volume confirms that the scientific potential of the epigenetics experts at VolitionRx Limited (VNRX) is capable of offsetting staffing shortages when scaling tests in the US market.